secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ernexa Therapeutics Inc. (ERNA)
CIK:        0000748592
Form:       8-K/A
Filed at:   2022-09-01T23:59:59+00:00
Accession:  0001140361-22-031997
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Brooklyn ImmunoTherapeutics CSO Kevin D'Amour resigns; separation agreement provides $311K severance
--------------------------------------------------------------------------------

- Dr. Kevin D'Amour's resignation as Chief Scientific Officer effective August 26, 2022.
- Separation agreement includes 9 months' base salary totaling $311,250 (less withholdings).
- Vested options on 57,296 shares exercisable for 90 days post-separation; all unvested equity forfeited.
- COBRA health premium paid for the 9-month severance period.
- D'Amour agrees to cooperation, non-disparagement, and a general release of claims.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/748592/000114036122031997/0001140361-22-031997-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/748592/000114036122031997/brhc10041542_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-031997

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer